Clorox vs. Colgate: One Pays Nearly 6%, but Is It a Dividend Trap?

A retirement-focused investor might consider owning Clorox (NYSE:CLX | CLX Price Prediction) and its 5.89% forward yield, or Colgate-Palmolive (NYSE:CL) and its 2.27% yield? On paper, Clorox looks like the obvious income pick. A closer look at the balance sheet, cash flow, and long-term record suggests the high yield reads more like a warning sign than a bargain.

The share prices account for much of the gap. Clorox shares fell 22.44% over the past year, while Colgate rose 23.55%. Clorox’s yield got bigger because its stock got cheaper, and that is the least comforting way for a yield to grow.

Current Income: Clorox Pays More Cash Today

Clorox pays $1.25 per quarter, or $5.00 a year. Colgate pays $0.53 per quarter, or $2.12 a year. Each dollar invested in Clorox produces much more cash for someone drawing income right now. Management also said on the August earnings call that the dividend will stay where it is: “At this point our commitment to support the dividend has not changed. As you know, we have a long track record here. The dividend has increased annually for a decade, and for now you should expect this to continue.” Winner: Clorox, on raw income alone.

Dividend Safety: Colgate’s Cash Machine Pulls Away

Clorox’s $5.00 annual dividend compares with fiscal 2026 adjusted EPS of $5.53 and fiscal 2027 adjusted EPS guidance of $5.70 to $6.00. That leaves only a thin buffer. Management admitted “the current payout is a bit elevated” and called it “something more transitory as we rebuild our gross margin.”

That margin recovery has a long way to go. Fourth-quarter gross margin fell 520 basis points to 41.3%. Fiscal 2026 operating cash flow dropped 37.61% to $612M, and management expects fiscal 2027 inflation above $200 million. The GOJO/Purell deal pushed total liabilities to $7.542B against shareholders’ equity of just $252M. Clorox plans to use free cash flow to pay off short-term debt and commercial paper over the next 12 to 18 months, and that cash can’t also fund dividend increases.

Colgate’s numbers are moving the other way. Its second-quarter gross margin rose 140 basis points to 61.5%, Latin America sales grew 13.7%, and management raised its Base Business EPS growth outlook to mid-single digits. Colgate generated $3.634B in free cash flow in 2025 and returned $2.9B to shareholders. Winner: Colgate.

Track Record and Volatility: Colgate by a Mile

Colgate has raised its dividend for 63 consecutive years, a Dividend Aristocrat run that exceeds Clorox’s decade of increases. Colgate’s quarterly payout went from $0.50 in 2024 to $0.52 in 2025 and $0.53 in 2026. Clorox’s latest raise took its payout from $1.24 to $1.25, a small step.

Over 10 years, Colgate shares gained 65.64% while Clorox slid 3.35%. Over five years, Colgate rose 38.98%, and Clorox fell 36.38%. Colgate also has a lower beta of 0.322, versus Clorox’s 0.574.

Clorox is cheaper at about 15 times forward earnings, compared with 21 for Colgate. Analysts still aren’t convinced. Clorox has 1 Buy, 14 Holds, 2 Sells and 2 Strong Sells, while Colgate has 6 Strong Buys, 7 Buys and zero Sells. Winner: Colgate.

Verdict: Colgate Belongs in the Retirement Core

Colgate-Palmolive is the better retirement stock. Its yield is lower, but its margins are growing; it generates billions in free cash flow; its stock swings less; and it has raised its dividend every year for more than six decades. For retirees who need steady, growing income they won’t have to worry about, Colgate is the stronger fit.

Clorox suits a narrower profile: an income seeker who can live with a possible dividend freeze and is willing to wait out the GOJO integration. The key question is whether gross margin gets back to the roughly 42% management guided for fiscal 2027 and whether debt comes down on schedule. Until both happen, Clorox’s yield is mostly pay for taking on risk, and Colgate is the safer foundation.

Contact [email protected] for any questions or corrections.